🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Discussing the latest updates in Chronic Myeloid Leukemia #CML at HemOnc Pulse meeting ✅ Looking for ways to improve #patient outcomes & access to treatment ✅ Panel discussion & insights on next steps in the field ✅ Connecting with colleagues & friends #HOPlive25 #leusm

T-DXd Plus Pertuzumab Could Disrupt First-Line SOC in HER2+ Metastatic Breast Cancer Dana-Farber News ASCO #ASCO25 #bcsm #oncology onclive.com/view/t-dxd-plu…

🎯

The study reflects real-world data from Italy 🇮🇹 —where access to care is streamlined. But in the U.S. 🇺🇸, without universal coverage and with major barriers like financial toxicity, what Dr. Sonya Reid, MD MPH presented is our harsh reality. We must confront this disparity—urgently.

Statin use was not associated with improved long-term outcomes in patients with early-stage HER2+ #BreastCancer, according to post hoc findings from the phase 3 APHINITY trial, which evaluated adjuvant pertuzumab/trastuzumab plus chemotherapy. Read here: hubs.ly/Q03qVydS0

Paolo Tarantino Nature Medicine I’m excited for the VEGF targeting bispecifics, but sadly I think what we really need in 1st line mTNBC is a VEGF/PD-1 bispecific plus TROP2 AD in a post Keynote 522 world. There, ya’ll got some free consulting! Who wants to get this trial going? #TNBC #breastcancer

We need more trials like this for #ILC. That’s why we launched the #PLUMB registry—to define MRD-adapted endpoints for drug efficacy in this often “invisible” disease. Let’s make lobular breast cancer seen. #Rita_Mukhtar Rebecca Shatsky, MD #Rachel_Jankowitz #Jo_Chien Lobular Breast Cancer Alliance

So thrilled that METAvivor was able to support UCSF Breast Care Center’s Dr Rita Mukhtar and the PLUMB registry!

Jason Mouabbi and Paolo Tarantino Discuss How T-DXd + Pertuzumab Could Reshape Frontline Treatment in HER2+ mBC Community Health Media Paolo Tarantino Jason A. Mouabbi MD oncodaily.com/blog/paolo-tar… #Cancer #CancerResearch #Medicine #Health #BreastCancer #mBC #Pertuzumab #MedX #MedNews #MedEd

Jason A. Mouabbi MD Rebecca Shatsky, MD Lobular Breast Cancer Alliance We would like to inform you that your post has been published on OncoDaily.com. Thank you for sharing. oncodaily.com/insight/midas-…

#ASCO25 Game-changer? #SERENA6 trial may redefine 2L therapy for #HR+/HER2– #BreastCancer. Early #ESR1 mutation detection via #LiquidBiopsy + #Camizestrant could improve outcomes. “It’s an inflection point.” —Jason A. Mouabbi MD bit.ly/3HzvueF #SABCS24 Genotyping image -National Cancer Institute

TDXd for Brain Metastases 🧠 Drs. Rena Callahan from David Geffen School of Medicine at UCLA and Aditya Bardia from UCLA Health illustrate how TDXd has become the preferred treatment for #HER2-breast #cancer patients with brain #metastases, reshaping clinical practice standards. #tdxd #breastcancer

Fantastic work Fadi Haddad, MD 👏🏼 👏🏼 👏🏼

👇Latest treatment & research updates on #RenalMedullaryCarcinoma. #endRMC #RareCancers #kidneycancer

What patients are eligible for adjuvant CDK4/6i? We looked at this in ConcertAI: the approval of ribo doubled the pts eligible for adjuvant CDK4/6i (15%➡️30%) and provided an option for 10% of pts with N0 disease, those with the most aggressive cancers. esmoopen.com/article/S2059-…

Leaving my 1st MD Anderson Cancer Center Saturday multiD clinic for pts with #breastCancer. I don't normally work on the weekends but this time it was worth it to get people more quickly on to a #bcsm treatment path. Loved working w/ Drs Richard Ehlers & Jason A. Mouabbi MD & the amazing MDA staff.

Ever wonder what happens right after an OncLive filming? We’re bringing you behind the scenes! We snagged Jason A. Mouabbi, MD for some candid thoughts after our latest OncLive Insights at ASCO. Watch the series: hubs.li/Q03sjT6V0 Jason A. Mouabbi MD #OncLiveInsights #BreastCancer

5/5 Numbers aren’t the enemy—they just need the right lens 🔍. Next time a survivorship stat looks scary, ask: “What does this mean given where I am today?” Conditional thinking can turn dread into perspective. #MedTwitter #StatTwitter #CancerSurvivorship #kidneycancer